Effects of Caffeine in Tinnitus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00628316 |
Recruitment Status :
Completed
First Posted : March 5, 2008
Last Update Posted : March 22, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Tinnitus | Dietary Supplement: caffeine | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effects of Caffeine Consumption on Tinnitus Perception |
Study Start Date : | January 2008 |
Actual Primary Completion Date : | September 2008 |
Actual Study Completion Date : | December 2008 |

- Dietary Supplement: caffeine
caffeine daily intake will be reduced form 150 ml per day
- Tinnitus Handicap Inventory [ Time Frame: 30 days ]
- Visual Analog Scale [ Time Frame: 30 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- tinnitus for more than 6 months
- THI > 38
- no central acting drugs in the last 6 months
- tympanogram type A-n
- daily intake of caffeine greater than 150 ml
Exclusion Criteria:
- vascular and muscular tinnitus
- concomitant TMJ disorders
- abnormal otoscopy
- mixed and conductive hearing losses
- Ménière disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00628316
Brazil | |
Faculdade de Medicina de Valença | |
Valença, RJ, Brazil, 27600-000 | |
OTOSUL Otorrinolaringologia Sul-Fluminense | |
Volta Redonda, RJ, Brazil, 27255-650 |
Study Chair: | Ricardo R Figueiredo, MD,MSc | Faculdade de Medicina de Valença |
Responsible Party: | Ricardo Rodrigues Figueiredo, MD, MSc, University of Valencia |
ClinicalTrials.gov Identifier: | NCT00628316 |
Other Study ID Numbers: |
FMV 001 2008 |
First Posted: | March 5, 2008 Key Record Dates |
Last Update Posted: | March 22, 2011 |
Last Verified: | February 2008 |
tinnitus caffeine |
Tinnitus Hearing Disorders Ear Diseases Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases Caffeine Central Nervous System Stimulants |
Physiological Effects of Drugs Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents |